CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

BACKGROUND: Osimertinib is an oral, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor activating mutation (EGFRm) and the resistance mutation (T790M) that is FDA approved for patients with EGFR mutant lung cancer. The synergism between Osimertinib and rad...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Rauf, Yasmeen, Kotecha, Rupesh, Fadul, Camilo, Evanoff, Wendi, Suh, John, Chao, Samuel, Murphy, Erin, Yu, Jennifer, Angelov, Lilyana, Barnett, Gene, Mohammadi, Alireza, Ahluwalia, Manmeet
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2020
Onderwerpen:
Clinical Trials: Immunologic
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651084/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.156
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items